Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI, Inc. (OTCQX: PYNKF) is a commercial-stage medical technology company whose news flow centers on the development, clinical use, and commercialization of its optical coherence tomography (OCT) imaging platforms for cancer surgery. Company updates frequently highlight the adoption of its FDA-cleared Perimeter S-Series OCT system in operating rooms across the United States, including agreements with major health systems and hospitals for tissue visualization during surgery.
News releases describe how surgeons at leading centers are using the S-Series OCT to obtain real-time, cross-sectional visualization of excised tissues at the cellular level, and how this imaging can provide additional insights for intraoperative decision-making. Perimeter also reports on progress with its investigational Perimeter B-Series OCT with Assist AI, a breakthrough-device-designated platform that combines OCT with artificial intelligence and has been evaluated in a pivotal clinical trial supported by a grant from the Cancer Prevention and Research Institute of Texas.
Investors following PYNKF can expect updates on commercial traction for the S-Series, including new hospital installations and systemwide agreements, as well as regulatory milestones related to the B-Series PMA review. The company’s news also covers participation in professional medical conferences, breast surgery forums, and investor events, along with capital raising activities intended to support commercialization and product development.
This news page aggregates Perimeter’s press releases and related coverage so readers can monitor developments in its OCT imaging technology, clinical collaborations, regulatory pathway, and corporate strategy. For those tracking small- and micro-cap medical technology names, the PYNKF news feed offers ongoing insight into how Perimeter is positioning its imaging platforms within cancer surgery and breast care.
Perimeter Medical Imaging AI (OTC:PYNKF), a leader in medical imaging technology, will participate in the 6th Annual Needham Virtual Med Tech & Diagnostics Conference on August 16-17, 2021. CEO Jeremy Sobotta will hold one-on-one virtual meetings during the event. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) offers real-time visualization of excised tissue, potentially enhancing surgical outcomes. The company is also developing the B-Series OCT with ImgAssist AI, backed by a $7.4 million CPRIT grant, aimed at improving breast conservation surgery outcomes.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has appointed Dr. Sarah Butler as Vice President of Clinical and Medical Affairs, effective immediately. CEO Jeremy Sobotta expressed enthusiasm over Butler's expertise in medical affairs, expecting her to enhance clinical strategies as the company prepares for a pivotal study of its ImgAssist AI software. Dr. Butler brings extensive experience from previous roles, including her tenure at IBM Watson Health. The company focuses on transforming cancer surgery with advanced imaging tools, addressing unmet medical needs.
Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced CEO Jeremy Sobotta will participate in the virtual Lytham Partners Summer 2021 Investor Conference panel on breast cancer innovations on June 15, 2021, at 5:00 PM ET. The event runs from June 14-16, 2021, with one-on-one meetings available. Perimeter's FDA-cleared S-Series Optical Coherence Tomography (OCT) enhances real-time visualization during surgery, aiming for improved patient outcomes. The B-Series OCT, supported by a $7.4 million CPRIT grant, is set for a pivotal study to evaluate its impact on breast cancer surgery.
Perimeter Medical Imaging AI (TSX-V:PINK)(OTC:PYNKF) has successfully completed the technology transfer for manufacturing its S-Series Optical Coherence Tomography (OCT) imaging systems with Minnetronix Medical. This milestone allows Perimeter to scale up production efficiently and meet customer demands. The Perimeter S-Series OCT, cleared by the U.S. FDA, provides real-time margin visualization in surgical settings, potentially improving patient outcomes. The company is also advancing its ImgAssist AI technology, supported by a $7.4 million grant, and plans a pivotal study to evaluate its effectiveness in breast conservation surgery.
Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported 2020 financial results and significant milestones. Key achievements included FDA 510(k) clearance for the S-Series OCT, paving the way for U.S. market entry. The company received a $7.4 million grant from CPRIT for its ATLAS AI project and appointed new leadership to strengthen its board. Notable future initiatives include a multi-site clinical study to assess re-operation rates in breast conservation surgery. The recent Breakthrough Device Designation from the FDA underscores the potential of its innovative technologies in enhancing surgical outcomes.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced that CEO Jeremy Sobotta will present a company overview at the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 21, 2021, at 4:00 p.m. ET. The company focuses on transforming cancer surgery with advanced imaging tools. Its Optical Coherence Tomography (OCT) Imaging System offers real-time visualization of tissue margins, enhancing surgical outcomes. Perimeter is advancing the ImgAssist AI technology with a $7.4 million grant, aiming to improve breast cancer surgery results.
Perimeter Medical Imaging AI (OTC:PYNKF) announced a physician-led webinar on its Optical Coherence Tomography (OCT) Imaging System, following its FDA 510(k) clearance. The system aids real-time tissue imaging during surgeries, enhancing margin visualization. The webinar features prominent surgeons discussing OCT technology's impact on breast cancer surgeries and future AI applications. CEO Jeremy Sobotta emphasized the company's commitment to commercialization and improving patient outcomes through advanced imaging tools.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced a new clinical study led by Dr. Beth DuPree, aiming to enroll 100 patients at Northern Arizona Healthcare. The study will evaluate the efficacy of Perimeter’s Optical Coherence Tomography (OCT) Imaging System during breast-conserving surgeries. This follows successful results from a prior 20-patient study. The new trial seeks to validate the technology's potential to reduce reoperations by providing real-time tissue visualization, aiming for better outcomes and lower healthcare costs.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) will be presenting at the Lytham Partners Spring 2021 Investor Conference on March 30, 2021, at 2:45 p.m. ET. CEO Jeremy Sobotta will provide a company overview highlighting their advanced imaging tools aimed at improving cancer surgery outcomes. The webcast can be accessed on the company's website, with an archived replay available after the event. Management will also engage in virtual one-on-one meetings during the conference, running from March 30 to April 1, 2021.
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) has successfully accelerated the expiry of certain share purchase warrants, raising approximately $8.3 million from the exercise of about 4.3 million warrants. This included 3,412,196 warrants exercised after February 1, 2021, yielding $6.8 million in cash. The funds will support the commercialization of their OCT Imaging system, recently cleared for U.S. market entry. CEO Jeremy Sobotta highlighted the importance of this support, which enhances the company's development efforts in addressing unmet surgical needs.
FAQ
What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?
What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?
